China Multiomics Market (2026-2031)
The China Multiomics Market was valued at $204.6 Million in 2026 and projected to reach to $384.9 Million by 2031, representing a compound annual growth rate of 13.5%. China's multiomics market is positioned for sustained growth through 2031, supported by government initiatives promoting precision medicine and significant investments in biotechnology infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Multiomics Market Trends and Insights
- China is leveraging its advanced biotechnology infrastructure and government support for precision medicine initiatives to drive multiomics adoption across research and clinical applications.
- The market in China is growing faster than the global average, reflecting strong investment in genomics, proteomics, and metabolomics technologies. China's multiomics sector benefits from increasing healthcare expenditure, rising prevalence of chronic diseases, and a growing emphasis on personalized medicine.
- China has positioned itself as a key hub for multiomics research, with major pharmaceutical and biotech companies establishing innovation centers.
- The forecast period through 2031 indicates China will continue to capture significant market share within the Asia Pacific region, driven by technological advancement and regulatory support for integrated omics platforms..
Key Market Statistics
- CAGR (2026-2031) 13.5% CAGR
- Market Size, 2026 ~USD 204.6 Million
- Forecast, 2031 ~USD 384.9 Million
- Country China
China Multiomics Market Overview
Rapid Market Growth :
China's multiomics market is expanding at 13.5% CAGR, outpacing the global average of 12.3%, driven by increasing investments in precision medicine and genomic research initiatives.
Government Support & Infrastructure :
China's advanced biotechnology infrastructure and strong government backing for precision medicine programs are accelerating multiomics adoption across both research institutions and clinical settings.
Market Valuation Trajectory :
The market is valued at $204.6 million in 2026 and is projected to nearly double to $384.9 million by 2031, reflecting sustained demand and technological advancement.
Clinical & Research Applications :
Multiomics integration is gaining traction in China's healthcare sector for disease diagnosis, drug development, and personalized treatment strategies across oncology and genetic disorders.
China Multiomics Market Dynamics
- The country's focus on developing domestic genomic capabilities and reducing reliance on imported diagnostic solutions is creating substantial opportunities for market expansion.
- Healthcare providers and research institutions are increasingly adopting multiomics approaches to enhance diagnostic accuracy and treatment outcomes. The competitive landscape in China is intensifying as both domestic and international players establish operations to capture market share.
- Integration of artificial intelligence with multiomics data analysis, coupled with declining sequencing costs, is expected to drive broader clinical adoption.
- Government policies supporting personalized medicine and the growing prevalence of chronic diseases will continue to fuel market momentum through 2031..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- China's multiomics market is valued at $204.6 million in 2026 and expected to grow to $384.9 million by 2031, representing a 13.5% CAGR.
- China's multiomics growth rate outpaces the global average of 12.3%, positioning the country as a regional growth leader.
- China's government support for precision medicine and biotechnology innovation is accelerating multiomics adoption in clinical and research settings.
- China's expanding healthcare infrastructure and rising chronic disease burden are key drivers of multiomics market expansion through 2031.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
China Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biotech & Diagnostics Companies : Companies seeking to expand multiomics product portfolios in China need market sizing, growth forecasts, and competitive analysis to guide R&D investments and commercialization strategies.
- Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in China's precision medicine sector require detailed market data, growth trajectories, and risk assessments for portfolio allocation decisions.
- Pharmaceutical Manufacturers : Drug developers leveraging multiomics for precision oncology and personalized medicine need China-specific market insights to identify partnership opportunities and clinical trial locations.
- Healthcare Institutions & Hospitals : Chinese hospitals and research centers planning multiomics integration require market intelligence on technology adoption trends, vendor landscapes, and reimbursement models.
- Government & Policy Makers : Chinese health authorities and policy organizations need comprehensive market data to inform precision medicine initiatives, funding allocations, and regulatory framework development.
Reasons to Buy this Report
- Market Size & Growth Data : Access precise valuation figures for China's multiomics market with detailed CAGR analysis, enabling accurate financial forecasting and investment decision-making for the 2026-2031 period.
- Competitive Intelligence : Understand the competitive landscape specific to China, including key players, market positioning, and strategic initiatives driving growth in this high-potential Asian market.
- Government Policy Insights : Gain clarity on China's precision medicine initiatives and biotechnology policies that are directly influencing multiomics adoption rates and creating market opportunities.
- Segment & Application Analysis : Identify high-growth segments within China's multiomics market, including clinical diagnostics, drug development, and research applications with specific revenue projections.
- Strategic Market Entry : Develop informed market entry strategies for China with localized insights on healthcare infrastructure, regulatory requirements, and customer adoption patterns in the multiomics sector.
Frequently asked questions
What is the current size of China's multiomics market?
China's multiomics market is estimated at $204.6 million in 2026 and is projected to reach $384.9 million by 2031.
What is the CAGR for China's multiomics market?
China's multiomics market is expected to grow at a compound annual growth rate of 13.5% from 2026 to 2031.
How does China's multiomics market growth compare to global trends?
China's multiomics market CAGR of 13.5% exceeds the global CAGR of 12.3%, indicating faster regional growth and increasing market importance.
What factors are driving growth in China's multiomics market?
Key drivers include government support for precision medicine, rising healthcare expenditure, increasing chronic disease prevalence, and technological advancement in integrated omics platforms.
Which applications are leading China's multiomics market expansion?
China's multiomics adoption is driven by genomics, proteomics, and metabolomics applications in both research institutions and clinical diagnostics settings.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- US Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- Japan Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
